Charles River Laboratories
Gene Therapy holds great promise for neurological diseases. Researchers are delivering these molecular treatments to the brain with precision and efficiency, in both small and larger animal species. This translation has armed scientists with potentially lifesaving treatments for humans. Working with a seasoned research partner like Charles River provides access to years of experience with every step of the process.
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the US and expanding into the EU. The SmartFlow® cannula is being used in partnership with over 20 biologics & drug delivery companies in various stages from preclinical research to late stage regulatory trials. More than 4,000 cases have been supported by our field-based clinical specialist team which offers support and services for our partners.
Invicro, a Konica Minolta Company
Invicro, a Konica Minolta Company is a leading CRO providing quantitative biomarker solutions, imaging core lab services, CAP/CLIA pathology services, advanced image analytics and software to support sponsors with their drug discovery and development programs. Invicro was founded in 2008 with offices, laboratories and clinics around the world that support leading pharmaceutical and biotechnology companies with their preclinical research, Phase 0-IV clinical trials and commercialization of companion diagnostics across a broad range of therapeutic areas.
At Certara, we support confident decision-making throughout the entire drug development process with our gold-standard software and technology-enabled services, helping our partners to reduce cycle times, lower costs, and improve outcomes for patients. In fact, eleven regulatory agencies worldwide have adopted our Phoenix™ PK/PD and/or Simcyp™ PBPK Simulator software platforms, including the US FDA and EMA. Our results speak for themselves. 90% of companies that received new drug approvals by the FDA in the past 6 years use our software or services.
Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We also provide non-GLP toxicology and biodistribution services in primates and rodents to support the development of gene-based therapies. We deliver cutting edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics.
Biomere and JOINN Labs announce the merger of a new premier, global nonclinical CRO with broad capabilities and experience in supporting gene therapy. With locations in the USA and China, we are ideally suited to help our clients advance their novel therapies
from early discovery through development.
Lonza provides contract development and manufacturing services that enable pharma and biotech companies to deliver medicines to patients. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of therapies. Together, let’s bring the next medicine to life.